Device to control circadian-effective light in Alzheimer's disease environments

项目摘要 这个拟议的项目将开发和现场测试一种准确监测和控制昼夜节律的设备。 阿尔茨海默病(AD)和阿尔茨海默病相关痴呆(ADRD)患者的刺激(CS) 养老院。人类生物学已经进化成有两个截然不同的光学系统：视觉系统，通过它 我们看到并处理图像，以及昼夜节律系统，它调节我们的生物钟和相关的 生物系统。这两个系统对光的光谱和时间响应有显著的不同 输入。具体地说，昼夜节律刺激在460 nm处达到峰值，并在几分钟后做出反应 激活，而视觉系统在555 nm处达到峰值，并几乎瞬间对输入做出反应。所有照明 在建筑物中设计和安装系统时只考虑了明视(视觉)系统 所有用于表征建筑物照明的测光表都被校准为测量光度，而不是CS。 虽然越来越多的研究记录了昼夜节律系统对人类的影响 健康，包括调节睡眠和改善AD/ADRD患者的认知，关于CS的研究 AD/ADRD患者所经历的情况极其有限。照明研究中心的研究人员 伦斯勒理工学院开发了日光计，这是一种测量昼夜节律的校准光度计 光和昼夜节律刺激。在该项目的第一阶段，研究人员修改了现有的基于工作站的 他们之前为视觉系统开发的照明控制系统包括日光计技术， 允许该控制系统记录CS测量结果。这些CS测量的准确性是 在实验室和现场确认-目前正在进行AD/ADRD护理中的20个设备的测试 家。在这一第二阶段的应用中，研究人员建议为该设备添加控制功能，以便照明 可控制以优化AD/ADRD患者环境中的CS剂量。基于机器学习的 照明控制算法将由连续的光级和光谱测量以及 定期(例如，每日)患者健康数据。来自这些设备的数据将被无线传输到 研究人员通过互联网网关和相关的基于云的数据管理系统。这些数据将 对于更好地了解AD/ADRD患者的CS暴露具有直接价值，并可以 最终导致新的照明系统和/或建筑规范，考虑到我们的视觉和生物钟 系统。在开发阶段之后，30个启用CS的照明控制系统将在 22周的测试期。研究人员的目标是在不久的将来将这种支持CS的照明控制系统商业化 完成这一实地测试和专门针对AD/ADRD疗养院的第二阶段项目 申请。

Project Summary This proposed project will develop and field-test a device that accurately monitors and controls the circadian stimulus (CS) for Alzheimer disease (AD) and Alzheimer-disease-related dementia (ADRD) patients in nursing homes. Human biology has evolved to have two distinct optical systems: the visual system, by which we see and process images, and the circadian system, which regulates our biological clock and associated biological systems. These two systems have significantly different spectral and temporal responses to optical input. Specifically, circadian stimulation peaks at 460 nm and responds after several minutes of optical activation, while the visual system peaks at 555 nm and responds nearly instantaneously to inputs. All lighting systems are designed and installed in buildings with consideration only given to the photopic (visual) system and all light meters used to characterize lighting buildings are calibrated to measure photopic light, not CS. While a broad and growing body of research has documented the impacts of the circadian system on human health, including regulating sleep and improving cognition in AD/ADRD patients, research on the CS experienced by AD/ADRD patients is extremely limited. Researchers at the Lighting Research Center at Rensselaer Polytechnic Institute developed the Daysimeter, a calibrated light meter that measures circadian light and circadian stimulus. In Phase I of this project, researchers modified an existing workstation-based lighting control system they previously developed for the visual system to include Daysimeter technology, allowing this control system to record CS measurements. The accuracy of these CS measurements was confirmed in the laboratory and field-testing of 20 of devices is currently ongoing in AD/ADRD nursing homes. In this Phase II application, researchers propose adding control features to this device so that lighting can be controlled to optimize CS dosages in AD/ADRD patient environments. Machine learning-based lighting control algorithms will be driven by continuous light level and spectrum measurements as well as periodic (e.g., daily) patient health data. Data from these devices would be wirelessly transmitted to researchers via an Internet gateway and associated cloud-based data management systems. These data would be of immediate value for gaining a better understanding of AD/ADRD patients' CS exposure and could ultimately result in new lighting systems and/or building codes that consider both our visual and circadian systems. Following the development phase, 30 CS-enabled lighting control systems will be field tested over a 22-week test period. Researchers aim to commercialize this CS-enabled lighting control system shortly after the completion of this field test and the Phase II project specifically targeting AD/ADRD nursing home applications.